<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149825</url>
  </required_header>
  <id_info>
    <org_study_id>R21MH066131</org_study_id>
    <secondary_id>R21MH066131</secondary_id>
    <secondary_id>DSIR 83-ATAS</secondary_id>
    <nct_id>NCT00149825</nct_id>
  </id_info>
  <brief_title>Combining Antidepressant Medication and Psychotherapy for Insomnia to Improve Depression Outcome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of a combination of antidepressant medication and
      sleep-focused psychotherapy to simultaneously treat sleep difficulties and depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Difficulties falling and/or staying asleep are common in people who suffer from depression.
      Persistent insomnia can hinder response to treatment. In addition, individuals whose insomnia
      does not resolve with standard antidepressant therapy are at increased risk for recurrence of
      their depression. Between 60% and 84% of people who have major depressive disorder report
      symptoms of insomnia. This study will assess the efficacy of combining antidepressant
      medication and sleep-focused psychotherapy to simultaneously treat sleep difficulties and
      depression.

      Participants in this double-blind study will be randomly assigned to receive either
      desensitization therapy or cognitive behavioral therapy to target insomnia. All participants
      will also receive escitalopram oxalate, an antidepressant medication. The study will last 12
      weeks. The severity of participants' depression and insomnia will be assessed. Study visits
      will occur weekly for the first 6 weeks, bi-weekly for the last 6 weeks, and once 6 months
      post-intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of Depression (%)</measure>
    <time_frame>After 12 weeks or at the last available time point</time_frame>
    <description>Percent of participants in depressive remission at 12 weeks. Remission of depression was required both an HRSD score ≤ 7 and absence of the two core symptoms of MDD based on the depression module of the SCID.
The HRSD (Hamilton Rating of Depression Scale) measure depressive symptom severity. TIt has 17 items. The score ranges between 0 and 48. A score below 7 represents minimal symptoms.
The SCID rates 9 symptoms of depression as present or absent. The two core symptoms of depression are sadness and anhedonia (low motivation and/or enjoyment in significant life domains).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission of Insomnia</measure>
    <time_frame>After 12 weeks or at the last available time point</time_frame>
    <description>Percent of participants in insomnia remission. Remission of insomnia was defined by an Insomnia Severity Index (ISI)score &lt; 8. The ISI (Insomnia Severity index) scores range between 0 and 38. A score &lt; 8 indicates absence of insomnia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>MED+CBTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram plus Cognitive Behavioral Therapy for Insomnia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MED+CTRL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram plus Pseudo-desensitization Therapy for Insomnia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>5 to 20 mg for 12 weeks</description>
    <arm_group_label>MED+CBTI</arm_group_label>
    <arm_group_label>MED+CTRL</arm_group_label>
    <other_name>Escitalopram plus Cognitive behavioral Therapy</other_name>
    <other_name>Escitalopram plus Pseudo-desensitization Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBTI</intervention_name>
    <description>Cognitive Behavioral Treatment for Insomnia</description>
    <arm_group_label>MED+CBTI</arm_group_label>
    <other_name>Cognitive Behavioral Treatment for Insomnia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CTRL</intervention_name>
    <description>Control Therapy consists of Pseudo-desensitization Therapy for Insomnia</description>
    <arm_group_label>MED+CTRL</arm_group_label>
    <other_name>Pseudo-desensitization Therapy for Insomnia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of major depressive disorder

          -  HRSD(17) score of at least 14

          -  Presence and complaint of insomnia for at least 1 month

          -  Fluent in English

          -  Use of an effective form of contraception throughout the study

        Exclusion Criteria:

          -  Other psychiatric disorders (e.g., bipolar disorder, post traumatic stress disorder,
             obsessive compulsive disorder, eating disorder)

          -  Psychotic symptoms

          -  Serious, unstable, or terminal medical condition

          -  Axis II diagnosis of antisocial, schizotypal, or severe borderline personality
             disorder

          -  Substance abuse

          -  Not willing to end other psychiatric treatment

          -  Previous electroconvulsive therapy or vagus nerve stimulation treatment during the
             last year

          -  Sleep apnea, restless leg, or periodic limb movement disorder (to be ruled out after
             first sleep study)

          -  Other sleep disorders

          -  Currently pregnant or breastfeeding

          -  History of seizure disorder

          -  Disease or condition that produces altered metabolism or hemodynamic responses

          -  Liver or kidney dysfunction

          -  Current use of any over the counter medications or herbs for mood or sleep benefits
             (e.g., melatonin, valerian, kava, hop extract, St. John's Wort, SAMe)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Manber, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University Medical School, Department of Psychiatry and Behavioral Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depression.stanford.edu</url>
    <description>Study Information Website</description>
  </link>
  <reference>
    <citation>Ong JC, Gress JL, San Pedro-Salcedo MG, Manber R. Frequency and predictors of obstructive sleep apnea among individuals with major depressive disorder and insomnia. J Psychosom Res. 2009 Aug;67(2):135-41. doi: 10.1016/j.jpsychores.2009.03.011. Epub 2009 Apr 25.</citation>
    <PMID>19616140</PMID>
  </reference>
  <results_reference>
    <citation>Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008 Apr;31(4):489-95.</citation>
    <PMID>18457236</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <results_first_submitted>July 30, 2009</results_first_submitted>
  <results_first_submitted_qc>September 11, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 14, 2009</results_first_posted>
  <last_update_submitted>May 12, 2014</last_update_submitted>
  <last_update_submitted_qc>May 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Rachel Manber</investigator_full_name>
    <investigator_title>Dr. Rachel Manber</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Sleep</keyword>
  <keyword>Mental Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited between June 2004 and August 2006 through newspaper advertisements, electronic bulletin boards, community postings, and brochures in clinics.</recruitment_details>
      <pre_assignment_details>Enrolled participants were screened to determine if inclusion exclusion criteria were met. This process included structured clinical interviews, completion of sleep logs, and an ambulatory screening sleep study to rule out other sleep disorders.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MED+CBTI</title>
          <description>Escitalopram plus cognitive behavioral therapy for insomnia</description>
        </group>
        <group group_id="P2">
          <title>MED+CTRL</title>
          <description>Escitalopram plus control therapy for insomnia in depression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Intolerance to medication side effects</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Time commitments</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not liking insomnia therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MED+CBTI</title>
          <description>Escitalopram plus cognitive behavioral therapy for insomnia</description>
        </group>
        <group group_id="B2">
          <title>MED+CTRL</title>
          <description>Escitalopram plus control therapy for insomnia in depression</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="13.6"/>
                    <measurement group_id="B2" value="47.8" spread="13.4"/>
                    <measurement group_id="B3" value="48.6" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission of Depression (%)</title>
        <description>Percent of participants in depressive remission at 12 weeks. Remission of depression was required both an HRSD score ≤ 7 and absence of the two core symptoms of MDD based on the depression module of the SCID.
The HRSD (Hamilton Rating of Depression Scale) measure depressive symptom severity. TIt has 17 items. The score ranges between 0 and 48. A score below 7 represents minimal symptoms.
The SCID rates 9 symptoms of depression as present or absent. The two core symptoms of depression are sadness and anhedonia (low motivation and/or enjoyment in significant life domains).</description>
        <time_frame>After 12 weeks or at the last available time point</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MED+CBTI</title>
            <description>Escitalopram plus cognitive behavioral therapy for insomnia</description>
          </group>
          <group group_id="O2">
            <title>MED+CTRL</title>
            <description>Escitalopram plus control therapy for insomnia in depression</description>
          </group>
        </group_list>
        <measure>
          <title>Remission of Depression (%)</title>
          <description>Percent of participants in depressive remission at 12 weeks. Remission of depression was required both an HRSD score ≤ 7 and absence of the two core symptoms of MDD based on the depression module of the SCID.
The HRSD (Hamilton Rating of Depression Scale) measure depressive symptom severity. TIt has 17 items. The score ranges between 0 and 48. A score below 7 represents minimal symptoms.
The SCID rates 9 symptoms of depression as present or absent. The two core symptoms of depression are sadness and anhedonia (low motivation and/or enjoyment in significant life domains).</description>
          <units>percent of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We hypothesized that compared with MED+CTRL, a greater percent of participants randomized to MED+CBTI will experience remission of depression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.13</p_value>
            <method>Chi-squared</method>
            <method_desc>This is a one-tailed test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission of Insomnia</title>
        <description>Percent of participants in insomnia remission. Remission of insomnia was defined by an Insomnia Severity Index (ISI)score &lt; 8. The ISI (Insomnia Severity index) scores range between 0 and 38. A score &lt; 8 indicates absence of insomnia.</description>
        <time_frame>After 12 weeks or at the last available time point</time_frame>
        <population>Included in the analysis were all participants who attended at least one post randomization visit.</population>
        <group_list>
          <group group_id="O1">
            <title>MED+CBTI</title>
            <description>Escitalopram plus cognitive behavioral therapy for insomnia</description>
          </group>
          <group group_id="O2">
            <title>MED+CTRL</title>
            <description>Escitalopram plus control therapy for insomnia in depression</description>
          </group>
        </group_list>
        <measure>
          <title>Remission of Insomnia</title>
          <description>Percent of participants in insomnia remission. Remission of insomnia was defined by an Insomnia Severity Index (ISI)score &lt; 8. The ISI (Insomnia Severity index) scores range between 0 and 38. A score &lt; 8 indicates absence of insomnia.</description>
          <population>Included in the analysis were all participants who attended at least one post randomization visit.</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We hypothesized that compared with MED+CTRL, a greater percent of participants in MED+CBTI will experience remission of insomnia.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MED+CBTI</title>
          <description>Escitalopram plus cognitive behavioral therapy for insomnia</description>
        </group>
        <group group_id="E2">
          <title>MED+CTRL</title>
          <description>Escitalopram plus control therapy for insomnia in depression</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of the current pilot study include a small sample size, relative racial homogeneity, and exclusion of patients with comorbidity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Rachel Manber, PhD</name_or_title>
      <organization>Stanford University, School of Medicine</organization>
      <phone>650-724-2377</phone>
      <email>Rmanber@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

